

SUPPLEMENTARY TABLE. Antiviral type and timing of treatment/prescription among children and adolescents with laboratory-confirmed influenza and medically attended illness who received or were prescribed antivirals—two multi-state surveillance networks, United States, 2023–24 influenza season

Characteristic	No. total (Col %*)		
	NVSN		FluSurv-NET
	Outpatient [†] (n = 177)	Inpatient (n = 148)	Inpatient (n = 1,136)
Antiviral treatment/ prescription			
Oseltamivir	177 (100)	147 (99)	1,115 (99)
Peramivir	—	1 (1)	5 (0)
Baloxavir marboxil	—	—	7 (0)
Oseltamivir and Peramivir	—	—	9 (1)
Zanamivir	—	—	—
Timing of antiviral treatment/prescription (days)[§]			
Before hospitalization/visit	—	4 (3)	44 (6)
0	176 (99)	101 (68)	707 (60)
1	1 (1)	37 (25)	342 (30)
2	—	3 (2)	23 (2)
≥3	—	3 (2)	19 (1)
Unknown	—	—	1 (0)

Abbreviations: FluSurv-NET= Influenza Hospitalization Surveillance Network; NVSN= New Vaccine Surveillance Network.

* Weighted % are calculated using sampling weights for FluSurv-NET

[†] Including outpatient clinics, urgent care clinics, and emergency departments. Only children and adolescents recommended to receive antiviral medication in the outpatient setting are included (specifically those aged <5 years or with one of the following medical condition categories: asthma/reactive airway disease or chronic lung disease, cancer, organ transplant, chronic metabolic disease, blood disorders, cardiovascular disease, neurologic disorders, immunocompromised, renal disease, liver disease, obesity [among children aged ≥2 years])

[§] Calculated as the number of days from medical encounter/hospital admission to date of antiviral treatment/prescription